Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
843
Views
2
CrossRef citations to date
0
Altmetric
Articles

Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

Molly E. Gravenoa Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5995-0308View further author information
ORCID Icon,
Alison Carullia Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Craig W. Freyera Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Brendan L. Mangana Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Robert Nietupskib Central Pharmacy Services, Adventist Health, Roseville, CA, USAView further author information
,
Alison W. Lorenc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Noelle V. Freyc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
David L. Porterc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Saar I. Gillc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Elizabeth O. Hexnerc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Selina M. Lugerc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Mary Ellen Martinc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Shannon R. McCurdyc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Alexander E. Perlc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Daria V. Babushokc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
&
Keith W. Pratzc Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USAView further author information
 show all
Pages 1645-1650 | Received 06 Jan 2022, Accepted 01 Feb 2022, Published online: 08 Mar 2022

References

  • Brandwein JM, Saini L, Geddes MN, et al. Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study. Am J Blood Res. 2020;10(4):124–133.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
  • DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-Centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724–e736.
  • Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
  • Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
  • DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
  • Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407.
  • Ganzel C, Ram R, Gural A, et al. Venetoclax is safe and efficacious in relapsed/refractory AML. Leuk Lymphoma. 2020;61(9):2221–2225.
  • Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552–1564.
  • Masarova L, DiNardo CD, Bose P, et al. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021;5(8):2156–2164.
  • Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253–E255.
  • Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol. 2019;98(8):1927–1932.
  • Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: mayo clinic series on 86 patients. Am J Hematol. 2020;95(12):1511–1521.
  • Wang YW, Tsai CH, Lin CC, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020;99(3):501–511.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Sandhu KS, Dadwal S, Yang D, et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2020;26(12):e322–e327.
  • Lee CJ, Savani BN, Mohty M, et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplant. 2019;54(4):519–530.
  • Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229–1235.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.